actal
sterling winthrop (nz) ltd (now skb nz or sanofi winthrop) - alexitol sodium 360mg - tablet - 360 mg - active: alexitol sodium 360mg
soliris- eculizumab injection, solution, concentrate
alexion pharmaceuticals inc. - eculizumab (unii: a3ulp0f556) (eculizumab - unii:a3ulp0f556) - eculizumab 300 mg in 30 ml - soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh) to reduce hemolysis. soliris is indicated for the treatment of patients with atypical hemolytic uremic syndrome (ahus) to inhibit complement-mediated thrombotic microangiopathy. limitation of use soliris is not indicated for the treatment of patients with shiga toxin e. coli related hemolytic uremic syndrome (stec-hus). soliris is indicated for the treatment of generalized myasthenia gravis (gmg) in adult patients who are anti-acetylcholine receptor (achr) antibody positive. soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (nmosd) in adult patients who are anti-aquaporin-4 (aqp4) antibody positive. soliris is contraindicated for initiation in patients with unresolved serious neisseria meningitidis infection [see warnings and precautions (5.1)] . risk summary limited data on outcomes of pregnancies that have occurred following soliris use in pregnant women have not identified a concern for specific adverse developmental outcomes (see data ). there are risks to the mother and fetus associated with untreated paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) in pregnancy (see clinical considerations ). animal studies using a mouse analogue of the soliris molecule (murine anti-c5 antibody) showed increased rates of developmental abnormalities and an increased rate of dead and moribund offspring at doses 2-8 times the human dose (see data ). the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations disease-associated maternal and/or fetal/neonatal risk pnh in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery. ahus in pregnancy is associated with adverse maternal outcomes, including pre-eclampsia and preterm delivery, and adverse fetal/neonatal outcomes, including intrauterine growth restriction (iugr), fetal death and low birth weight. data human data a pooled analysis of prospectively (50.3%) and retrospectively (49.7%) collected data in more than 300 pregnant women with live births following exposure to soliris have not suggested safety concerns. however, these data cannot definitively exclude any drug-associated risk during pregnancy, because of the limited sample size. animal data animal reproduction studies were conducted in mice using doses of a murine anti-c5 antibody that approximated 2-4 times (low dose) and 4-8 times (high dose) the recommended human soliris dose, based on a body weight comparison. when animal exposure to the antibody occurred in the time period from before mating until early gestation, no decrease in fertility or reproductive performance was observed. when maternal exposure to the antibody occurred during organogenesis, two cases of retinal dysplasia and one case of umbilical hernia were observed among 230 offspring born to mothers exposed to the higher antibody dose; however, the exposure did not increase fetal loss or neonatal death. when maternal exposure to the antibody occurred in the time period from implantation through weaning, a higher number of male offspring became moribund or died (1/25 controls, 2/25 low dose group, 5/25 high dose group). surviving offspring had normal development and reproductive function. risk summary although limited published data does not report detectable levels of eculizumab in human milk, maternal igg is known to be present in human milk. available information is insufficient to inform the effect of eculizumab on the breastfed infant. there are no data on the effects of eculizumab on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for soliris and any potential adverse effects on the breastfed child from eculizumab or from the underlying maternal condition. safety and effectiveness of soliris for the treatment of pnh, gmg, or nmosd in pediatric patients have not been established. the safety and effectiveness of soliris for the treatment of ahus have been established in pediatric patients. use of soliris in pediatric patients for this indication is supported by evidence from four adequate and well-controlled clinical studies assessing the safety and effectiveness of soliris for the treatment of ahus. the studies included a total of 47 pediatric patients (ages 2 months to 17 years). the safety and effectiveness of soliris for the treatment of ahus appear similar in pediatric and adult patients [see adverse reactions (6.1), and clinical studies (14.2) ]. administer vaccinations for the prevention of infection due to neisseria meningitidis , streptococcus pneumoniae and haemophilus influenzae type b (hib) according to acip guidelines [see warnings and precautions (5.1, 5.3)] . fifty-one patients 65 years of age or older (15 with pnh, 4 with ahus, 26 with gmg, and 6 with nmosd) were treated with soliris in clinical trials in the approved indications. although there were no apparent age-related differences observed in these studies, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients.
ultomiris 100mgml
alexion pharma israel ltd - ravulizumab - concentrate for solution for infusion - ravulizumab 100 mg/ml - ravulizumab - ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (pnh): * in patients with haemolysis with clinical symptom(s) indicative of high disease activity. * in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome ahus who are complement inhibitor treatment naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. ultomiris is indicated in the treatment of adult patients with generalized myasthenia gravis (gmg) who are antiacetylcholine receptor (achr) antibody-positive.
kanuma
alexion pharma israel ltd - sebelipase alfa - concentrate for solution for infusion - sebelipase alfa 2 mg / 1 ml - sebelipase alfa - kanuma is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase (lal) deficiency.
laxitol
mega lifesciences (australia) pty ltd - macrogol 3350, quantity: 1 g/g - solution, powder for - excipient ingredients: - decrease/reduce/relieve constipation ; aperient/laxative ; helps reduce occurrence of constipation
flexitol wart remover gel
lacorium health international pty ltd - arnica montana,lactic acid,salicylic acid -
flexitol anti fungal liquid
lacorium health international pty ltd - undecenoic acid, quantity: 250 mg/g - liquid, multipurpose - excipient ingredients: eucalyptus oil; urea; hypromellose; aloe vera; isopropyl alcohol; melaleuca oil; purified water; dl-alpha-tocopheryl acetate; butylated hydroxytoluene
flexitol foot & knee pain relief gel
lacorium health international pty ltd - wintergreen oil, quantity: 100 mg/g (equivalent: methyl salicylate, qty 100 mg/g) - gel - excipient ingredients: peg-40 hydrogenated castor oil; ethanol; arnica montana; peppermint oil; benzyl alcohol; purified water; polyacrylamide; c13-14 isoparaffin; laureth-7; mixed (low-alpha type) tocopherols concentrate; soya oil
kanuma 20mg10ml concentrate for solution for infusion vials
alexion pharma uk ltd - sebelipase alfa - solution for infusion - 2mg/1ml
strensiq 18mg0.45ml solution for injection vials
alexion pharma uk ltd - asfotase alfa - solution for injection - 40mg/1ml